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Research
health outcomes. Previous studies have pro-
vided significant and useful knowledge
about several determinants of non-adher-
ence and effective interventions.2,3
Non-adherence to drug therapy for







Objective:  To investigate whether responses to a previously validated four-item 
medication adherence questionnaire were associated with adverse cardiovascular 
events.
gn:  Survey conducted among a cohort of participants in the Second Australian 
nal Blood Pressure Study.
ng:  Australian general practice.
cipants:  4039 older people with hypertension.
 outcome measures:  All major cardiovascular events or death; first specific 
ovascular event.
Results:  Subjects who adhered to their medication regimen (compared with non-
adherent subjects) were significantly less likely to experience a first cardiovascular event 
or a first non-fatal cardiovascular event (hazard ratio [HR] for both, 0.81; 95% CI, 0.67–
0.98; P = 0.03); a fatal other cardiovascular event (HR, 0.68; 95% CI, 0.48–0.99; P = 0.04); 
or a first occurrence of heart failure (HR, 0.58; 95% CI, 0.37–0.90; P = 0.02). Those who 
answered yes to “Did you ever forget to take your medication?” were significantly 
more likely to experience a cardiovascular event or death (HR, 1.28; 95% CI, 1.04–1.57; 
P = 0.02); a first cardiovascular event or death (HR, 1.31; 95% CI, 1.07–1.60; P = 0.01); 
a first cardiovascular event (HR, 1.34; 95% CI, 1.09–1.65; P = 0.01); or a first non-fatal 
cardiovascular event (HR, 1.35; 95% CI, 1.09–1.66; P = 0.01). Those who answered yes to 
“Sometimes, if you felt worse when you took your medicine, did you stop taking it?” 
were significantly more likely to experience a first occurrence of heart failure (HR, 2.06; 
95% CI, 1.16–3.64; P = 0.01).
Conclusions:  Subjects who adhered to their medication regimen were less likely to 
experience major cardiovascular events or death. The question relating to forgetting to 
take medication identified non-adherent subjects likely to experience a cardiovascular 
event or death. Clinicians could use this question to identify patients with hypertension 
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A erence is defined as “the extent toich a person’s behaviour coin-des with medical or health
advice”.  If such advice is evidence-based,
non-adherence is likely to lead to adverse
contributor to the less than ideal levels of
blood pressure control seen in the commu-
nity.4 However, there have been no studies
of links between adherence to cardiac medi-
cation and major adverse cardiovascular
outcomes.
A specific, four-question patient question-
naire has been shown to provide good spe-
cificity for drug adherence.5 We postulated
that this instrument could help doctors
identify patients who did not adhere to their
medication regimen and therefore were
most at risk of adverse cardiovascular events
or death. This would allow them to inter-




A postal survey of medication adherence
was undertaken in September and October
2000 of all 6018 surviving participants in
the Second Australian National Blood Pres-
sure Study (ANBP2).6 Non-responders were
not followed up. Data relating to partici-
pants’ demographic characteristics, cardio-
vascular risk factors, and outcomes were
accessed from the ANBP2 database.
ANBP2 was a large randomised controlled
t ri a l  o f  therapy  fo r  h yp er tens ion
( 160 mmHg systolic or  90 mmHg
diastolic blood pressure [if systolic blood
pressure was  140 mmHg]) in men and
women aged 65–84 years at trial entry:
diuretic medication was compared with
angiotensin-converting enzyme (ACE)
inhibitors. ANBP2 participants were
recruited from March 1995 to July 1998.
ANBP2 closed in September 2001; the
median follow-up period was 4.1 years.
Questionnaire
A short, validated patient questionnaire (the
Morisky instrument; Box 1) was used to
determine medication adherence.5 The rates
of all cardiovascular events, deaths or the
various cause-specific events (eg, coronary
events [myocardial infarction, sudden cardiac
death], cerebrovascular events [stroke] and
other cardiovascular events [heart failure,
ruptured aortic aneurysm]) experienced by
subjects were compared between those who
adhered or did not adhere to their medication
regimen. The adherent group were those who
answered “no” to each question (or no to
each question completed) and the non-
adherent group were those who answered
“yes” to any question. We also compared
subjects according to their response to each
of the four questions separately.
Statistical analysis
Analyses were carried out using SAS, version
9.1 (SAS Inc, Cary, NC, USA). Cox regres-
1 The Morisky instrument5
1. Did you ever forget to take your 
medication?
2. Were you careless at times about taking 
your medication?
3. When you felt better, did you sometimes 
stop taking your medication?
4. Sometimes, if you felt worse when you 
took your medicine, did you stop taking it?JA • Volume 185 Number 9 • 6 November 2006 487
RESEARCHsion using the method of Wei, Lin and
Weissfeld was used to model multiple times
to events within “subject”, and to allow for
clustering of subjects within “practi-
tioner”.7,8 The primary outcome was defined
as any cardiovascular event or death from
any cause. Further analyses were performed
on the time to first specific cardiovascular
event. Estimates were adjusted for age and
sex. Hazard ratios with 95% confidence
intervals and two-sided P values are pre-
sented. The significance level was set at
0.05.
We also compared systolic and diastolic
blood pressure measurements at baseline
and after the survey (most recent measure-
ment), and the difference between changes
in blood pressure levels of adherent and
non-adherent subjects to investigate
whether such responses were related to
adherence or non-adherence to their antihy-
pertensive medication regimen.
RESULTS
The characteristics of the ANBP2 cohort are
reported elsewhere.6 Replies were received
from 4039 of 6018 subjects (response rate,
67%). One hundred and twenty-seven sub-
jects answered none of the four questions,
328 answered at least one but not all four,
and 3584 answered all four questions. Of
the 328 subjects giving incomplete
responses, 181 were categorised as adherent
and 147 as non-adherent. Baseline charac-
teristics of responders and non-responders
to the questionnaire were similar; however,
responders were younger, less likely to
smoke, and more likely to be physically
active. Baseline characteristics of the adher-
ent and non-adherent groups were similar.
Details are available from the authors.
The incidence of any cardiovascular event
or death among survey responders was 39.1
per 1000 person-years, versus 99 per 1000
person-years in non-responders (hazard
ratio [adjusted for age and sex as per the
main study], 0.38; 95% CI, 0.33–0.42;
P < 0.0001).
A total of 2614 subjects (67% of those
who responded to any of the adherence
items) were, by our definition, adherent to
their medication regimen. Adherent sub-
jects, compared with non-adherent sub-
jects, were marginally less likely to
experience a cardiovascular event or death;
and were significantly less likely to experi-
ence a first cardiovascular event or first
non-fatal cardiovascular event, fatal other
cardiovascular event or first occurrence of
heart failure (Box 2).
The effects of adherence judged by
responses to each individual question were
also analysed (Box 3). A response of yes to
Question 1“Did you ever forget to take your
medication?” was associated with a signifi-
cant hazard for all cardiovascular events or
death from any causes; first cardiovascular
event or death from any causes; first cardio-
vascular event; and first non-fatal cardiovas-
cular event (Box 3). A response of yes to
Question 4 “Sometimes, if you felt worse when
you took your medicine, did you stop taking it?”
was associated with a significant hazard for
first occurrence of heart failure (Box 3).
There were no significant effects related to
whether subjects who were non-adherent
were careless taking their medication, or
stopped taking it because they felt better.
Unadjusted comparisons of baseline and
post-survey systolic and diastolic blood
pressure measurements by overall adher-
ence showed that subjects adhering to their
medication had a lower mean systolic blood
pressure (0.7 mmHg) and a significantly
greater fall in mean systolic blood pressure
compared with those who were non-adher-
3 Adjusted effect (rates are per 1000 person-years) of response to each 
question on total cardiovascular events, deaths and cause-specific events 
* Hazard ratios are adjusted for age and sex. † Only significant associations are shown. ◆
Outcome
Adherence 
response Rate Hazard ratio* (95% CI) P†
Did you ever forget to take your medication? Yes: n = 902; No: n = 2953
All cardiovascular events or 
death from any cause
Yes 50.3 1.28 (1.04–1.57) 0.02
No 35.2 1.00
First cardiovascular event 
or death from any cause
Yes 36.3 1.31 (1.07–1.60) 0.01
No 27.1 1.00




Yes 34.3 1.35 (1.09–1.66) 0.01
No 24.8 1.00
Sometimes, if you felt worse when you took your medicine, did you stop taking it? 
Yes: n = 418; No: n = 3246
First occurrence of heart 
failure
Yes 8.3 2.06 (1.16–3.64) 0.01
No 4.1 1.00
2 Adjusted effect (rates are per 1000 person-years) of overall adherence with 
medication (Yes: n= 2614; No: n= 1298) on total cardiovascular events, deaths 
and cause-specific events
* Hazard ratios are adjusted for age and sex. † Only significant associations are shown. ◆
Outcome
Adherence 
response Rate Hazard ratio* (95% CI) P†
All cardiovascular events or 
death from any cause
Yes 35.9 0.83 (0.69–1.00) 0.05
No 45.3 1.00
First cardiovascular event 
or death from any cause
Yes 27.5 0.83 (0.68–1.00) 0.05
No 33.3 1.00




Yes 25.2 0.81 (0.67–0.98) 0.03
No 31.1 1.00
Fatal other cardiovascular 
event
Yes 9.6 0.68 (0.48–0.99) 0.04
No 14.4 1.00
First occurrence of heart 
failure
Yes 3.6 0.58 (0.37–0.90) 0.02
No 6.3 1.00488 MJA • Volume 185 Number 9 • 6 November 2006
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Paradoxically, although subjects who
reported that they did not forget to take
their medication had a lower mean diastolic
blood pressure (0.1 mmHg), the fall in
diastolic blood pressure they experienced
was significantly less (0.8 mmHg; P = 0.02)
than that in non-adherent subjects.
DISCUSSION
We found that responses to a four-item
questionnaire were likely to identify individ-
uals with a higher risk of major adverse
cardiovascular events, including death.
Non-adherence was significantly associated
with a first cardiovascular event; a first non-
fatal cardiovascular event; a fatal other
cardiovascular event; and a first occurrence
of heart failure (Box 2). Non-adherence was
also associated, although with marginal sig-
nificance, with all cardiovascular events or
death from any cause (the primary endpoint
for ANBP2) and a first cardiovascular event
or death from any cause.
Of the four questions we asked the sub-
jects, the one relating to forgetting to take
medication seemed to best identify non-
adherent subjects likely to experience a car-
diovascular event or death. Furthermore,
comparisons of baseline and first systolic
and diastolic blood pressure readings after
the survey for adherent and non-adherent
subjects, as well as the responses to the
individual questions, suggested that subjects
who reported being adherent were truly
more adherent.
Non-adherence to drug therapy is a major
contributor to failure to control hyperten-
sion in the general community. Detection
and measurement of non-adherence in clini-
cal practice is difficult.9 The strategies devel-
oped to identify this problem usually
involve surrogate measures such as pill
count, pharmacy records or blood pressure
recordings, rather than hard endpoints such
as major adverse cardiovascular events.
However, pill counts are not accurate with
long-term medications, and patients do not
bring their medication packs with them at
the time of consultation.10 Pharmacy
records have shown good validity, but are
rarely used for a variety of professional,
acceptability and organisational reasons.11
We used a specific short four-question
patient questionnaire — the Morisky instru-
ment — which has been shown to provide
good specificity.5 We found that responses
to these questions correlated with cardiovas-
cular events or death in participants in the
ANBP2 hypertension trial. We chose the
Morisky instrument for its practicality and
utility. Other validated tools are available
but are more complex. For example, the
Hill–Bone Compliance Scale has 14 items
and the COMpliance Praxis Survey (COM-
PASS) has 12 items.12,13
Our study was a survey conducted among
a cohort of subjects participating in the
ANBP2. All data were collected prospec-
tively for the ANBP2. The cross-sectional
data collected in our survey were compared
with cardiovascular disease endpoint data
collected up to that point and until the end
of the trial (ie, retrospectively and prospec-
tively). The usual biases associated with the
use of retrospective data were minimised, as
the data were collected prospectively for the
purpose of the clinical trial.
The response rate was 67%. Subsequent
mail-outs did not occur because these items
were attached to a substudy questionnaire
(which did not have funding for further
mail-outs). In ANBP2, the vital status was
known for all but two of the cohort of 6083
after a median follow-up of 4.1 years.
Our finding that the cardiovascular dis-
ease event rate of non-responders was more
than twice that of responders suggests that a
confounding factor may have been that
some ANBP2 participants were too ill to
respond. We also found some small but
significant differences in the distributions of
a range of baseline characteristics of
responders compared with non-responders.
In conclusion, subjects who adhered to
their medication regimen were marginally
less likely to experience some types of
cardiovascular events. Of the four questions
asked, the first one “Did you ever forget to
take your medication?” identified participants
significantly more likely to experience a
cardiovascular event or death. A clinician
asking this question therefore may be able to
identify individuals who may benefit from
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